865980-54-7

Basic information

• Product Name: Methyl 4-AMino-1-AdaMantane Carboxylate
• Synonyms: Methyl 4-AMino-1-AdaMantane Carboxylate;Methyl 4-aminoadamantane-1-carboxylate
• CAS NO: 865980-54-7
• Molecular Formula: C₁₂H₁₉NO₂
• Molecular Weight: 209.28476
• Mol File: 865980-54-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 343.8°C at 760 mmHg
• Flash Point: 161.7°C
• Appearance: /
• Density: 1.267g/cm³
• Vapor Pressure: 1.23E-05mmHg at 25°C
• Refractive Index: 1.587
• CAS DataBase Reference: Methyl 4-AMino-1-AdaMantane Carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-AMino-1-AdaMantane Carboxylate(865980-54-7)
• EPA Substance Registry System: Methyl 4-AMino-1-AdaMantane Carboxylate(865980-54-7)

Safety Data

• Hazardous Substances Data: 865980-54-7(Hazardous Substances Data)

Usage

Description

Methyl 4-Amino-1-Adamantane Carboxylate is a chemical compound with the molecular formula C12H21NO2. It is a derivative of adamantane, a diamondoid hydrocarbon, featuring a methyl group, an amino group, and a carboxylate group. This versatile chemical is widely used in organic synthesis and medicinal chemistry research as a building block or precursor for the preparation of various pharmaceutical compounds and bioactive molecules. Its potential pharmacological activities and therapeutic applications in treating various diseases and conditions have attracted significant interest in the scientific community.

Uses

Used in Organic Synthesis:
Methyl 4-Amino-1-Adamantane Carboxylate is used as a building block in organic synthesis for the preparation of various chemical compounds. Its unique structure and functional groups make it a valuable component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Methyl 4-Amino-1-Adamantane Carboxylate is used as a precursor for the development of pharmaceutical compounds and bioactive molecules. Its potential pharmacological activities and ability to interact with biological targets make it a promising candidate for drug discovery and design.
Used in Pharmaceutical Industry:
Methyl 4-Amino-1-Adamantane Carboxylate is used as an active pharmaceutical ingredient or a key intermediate in the synthesis of various drugs. Its unique properties and potential therapeutic applications contribute to the development of novel medications for the treatment of different diseases and conditions.
Used in Drug Design and Development:
Methyl 4-Amino-1-Adamantane Carboxylate is employed as a key component in drug design and development, where its structural and functional characteristics are utilized to create new molecules with desired pharmacological properties. Its potential as a therapeutic agent and its ability to modulate biological processes make it a valuable asset in the pharmaceutical industry.

InChI:InChI=1/C11H17NO2/c12-9-7-1-6-2-8(9)5-11(3-6,4-7)10(13)14/h6-9H,1-5,12H2,(H,13,14)

Upstream product

• 67-56-1 methanol 
• 1057343-95-9 4-amino-adamantane-1-carboxylic acid 
• 56674-88-5 methyl 4-oxoadamantane-1-carboxylate 
• 56674-87-4 4-oxoadamantane-1-carboxylic acid 
• 20098-14-0 chemantane 

Downstream Products

• 1214727-54-4 C₂₀H₂₅NO₄ 
• 1265898-46-1 C₂₂H₂₆Cl₂N₂O₅S₂ 

Relevant articles and documents

NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

COMPOUND HAVING 11 ?-HSD1 INHIBITORY ACTIVITY

The present invention provides compounds having excellent 11β-HSD1 inhibitory activity. A compound represented by the following formula (I): [wherein X1 represents an oxygen atom, or the formula -(CR11R12)p-, etc., Y1 represents a hydrogen atom, a hydroxyl group, etc., Z1 represents an oxygen atom or the formula -(NR14)-, R1 represents a hydrogen atom, a halogen atom, a cyano group, a C1-4 alkyl group, a C1-4 alkyl group substituted with 1 to 3 halogen atoms, a C1-4 alkoxy group, a C1-4 alkoxycarbonyl group, a carboxyl group, a carbamoyl group, or an amino group, and m represents an integer of 1 or 2, and R2 represents a hydrogen atom or a C1-4 alkyl group, and n represents an integer of 1 or 2].

N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE

Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds